U.S. markets closed

Theravance Biopharma, Inc. (TBPH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.14+0.03 (+0.30%)
At close: 04:00PM EDT
10.14 0.00 (0.00%)
After hours: 04:14PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inverted Hammer

Inverted Hammer

Previous Close10.11
Bid9.40 x 800
Ask10.50 x 2200
Day's Range10.04 - 10.28
52 Week Range7.30 - 13.17
Avg. Volume1,001,850
Market Cap677.174M
Beta (5Y Monthly)0.66
PE Ratio (TTM)N/A
EPS (TTM)-2.02
Earnings DateNov 01, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.57
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for TBPH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Theravance Biopharma, Inc.
    INVA: What does Argus have to say about INVA?INNOVIVA INC has an Investment Rating of HOLD; a target price of $13.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • PR Newswire

    Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares

    Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced a "modified Dutch auction" tender offer (the "Offer") to purchase up to $95 million of its ordinary shares, par value $0.00001 per share (the "Shares").

  • Zacks

    Company News for Sep 20, 2022

    Companies in The News Are: WIX,COIN,TBPH,GSK,MRNA

  • Benzinga

    Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings

    Theravance Biopharma Inc (NASDAQ: TBPH) is buying back over 9.6 million shares from GSK plc (NYSE: GSK) for roughly $94 million, according to an SEC filing. In addition, Theravance plans to buy back $95 million from its existing investors "in the near term" and another $60 million in its shares on the open market. In a press release, Theravance says it hopes to complete that part of its plan by the end of 2023. Related content: Theravance Biopharma's Ampreloxetine Shows Benefit In Atrophy Patien